Comprehensive Healthcare Change Proposal

Reducing Blood Culture Contamination at McLeod Health: Lori, Implementing Steripath Device Student’s Name Course Professor’s Name Institution Name Date Reducing Blood Culture Contamination at McLeod Health: Lori, Implementing Steripath Device A1. Innovative Change The new innovation suggested to McLeod Health Loris in Loris, South Carolina, is the application of the Steripath Initial Specimen Diversion Device to gather blood cultures. Contamination of blood culture in hospitals is a widespread issue in the United States that predisposes patients to a false-positive diagnosis, antibiotic prescriptions, hospitalization, and increased health care costs. Among McLeod Health Loris, a reduction in the number of cases of contamination is necessary to improve patient outcomes and generate efficient utilization of resources. Steripath is an innovation that is value-based because it involves redirecting the specimen with maximum risk of contamination to the source of the contamination. The studies developed within some of the largest health care systems show that, with the aid of Steripath, the number of contamination cases decreases to less than 1% of the national standards proposed by the Clinical and Laboratory Standards Institute (CLSI, 2022). The technology is also advantageous because it enhances the quality of diagnosis through reducing redundant treatment, enhancing the care of patients, and reducing costs, which are the key areas of concern in value-based models of care. Deploying Steripath will help McLeod Health Loris demonstrate the willingness to be innovative, patient-centered, and evidence-based. This device has been effectively employed in other institutions, hence it can be trusted to deliver a solution to a well-documented clinical problem. A1. a. Authorized Proposed Change. See attached verification form. A1. b. Organizational Sponsor Discussion During the interview with the organizational sponsor, we talked about how the contamination of the blood cultures influences patient outcomes and hospital performance. The sponsor endorsed the initiative and observed that a reduction in false positives is required since they would reduce the unnecessary administration of antibiotics. The potential financial advantages of the shortening of hospital stays and the hospital-acquired complications were highlighted by the sponsor as well. Feedback involved making sure that training and education of staff become a priority in the implementation process because the effectiveness of the device relies on its correct use. Moreover, the sponsor suggested the creation of a strategy to track adherence by the nursing staff and laboratory personnel. A1. C. Proposed Changes The feedback of the sponsor indicated that the proposal itself did not need any alteration, but the implementation plan was adjusted to concentrate on the staff training and compliance monitoring. The changes will render the proposal more robust as it will make sure that the innovation is implemented cohesively and efficiently across the hospital. A2. Data to Support the Need for Change Blood culture contamination is a widespread problem in hospitals across the United States. Nationally, contamination rates range between 2% and 6%, well above the recommended benchmark of 1% set by the Clinical and Laboratory Standards Institute (CLSI, 2022). Each contaminated blood culture can lead to false-positive results, unnecessary testing, additional antibiotic use, and prolonged hospital stays. According to research, a single contaminated blood culture increases patient costs from $7,500 to $12,500 because of increased length of hospital stays, laboratory work, and antibiotic therapy (Goldberg & Goldberg, 2024). In McLeod Health Loris, like many other community hospitals, every dollar of healthcare expenditure counts. Ensuring quality care while reducing unnecessary costs should always be a priority. Currently, many small emergency departments face contamination due to the number of patients served, low staffing, and inconsistent blood draw procedures. In case the contamination rates remain high, the hospital risks patients being dissatisfied, financial losses, and even facing fines within the value-based care reimbursement schemes. The Steripath initial specimen diversion device provides an efficient remedy to this issue. Various peer-reviewed reports of multiple hospital systems show sustained contamination rates below or equal to 1 percent when using Steripath. Indicatively, Stanford Healthcare was documented to have zero contamination of blood cultures and virtually zero false positives when using Steripath (Grace, 2023). Moreover, a study utilizing the Steripath, which is an Initial Specimen Diversion Device (ISDD), reported a contamination rate of blood culture of 0.8% and a substantial decrease compared with the rate of 4.1% in the traditional approach (Wilber et al., 2023). These findings reveal that Steripath is clinically effective and economically worthy. When McLeod Health Loris implements the device, it is likely that the hospital will see drastic changes: contamination rates will decrease, diagnostic accuracy will rise, the number of unnecessary antibiotics will decrease, and the cost savings can be measured. This fact goes a long way in justifying the necessity of using Steripath as a novel value-based change at McLeod Health Loris. A3. Change Barriers Although the Steripath device has been demonstrated to lower blood culture contamination in most hospitals, there are various challenges that can come with its implementation at Macleod Health Loris. Some of the challenges include staff resistance to change and financial challenges. One of the main challenges is the financial limitations. As with many community hospitals, McLeod Health Loris has limited budgets and must make critical decisions regarding where budgets are spent. Purchasing Steripath equipment, training the staff, and changing the workflows demand initial investments. Although long-term cost savings are anticipated, decision-makers would be reluctant to invest in a new device because other priorities, including staffing or equipment upgrades, must be financed as well. This is a financial issue that may be a delaying factor in approving the project. Another main challenge that might affect its implementation is the employees' resistance to change. In most cases, employees, including nurses, laboratory personnel, and phlebotomists, are more used to their current methods of collecting blood cultures. Implementing a new device also means requesting them to learn a new process; this may seem time-consuming or unnecessary to some. Employees might fear Steripath will slow down their working process, particularly in the busy emergency department, where time is critical. Without the proper education and communication, some might even view the solution as an extra burden to Steripath instead of a solution. Planning and leadership support may help in dealing with both barriers. Concerning financial aspects, it is important to provide data showing how Steripath saves the total amount of money hospitals spend on false positives and unwanted treatments. To overcome perceptions among employees, proper training and demonstrations may be used to show how easy it is to operate the Steripath and how it assists in patient outcomes. Resistance can also be minimized by involving the frontline staff in the process at the beginning. In general, financial constraints and employees' resistance are real issues, but not impossible to overcome. These barriers can be reduced by having good leadership, education, and justification based on evidence to make the implementation of the Steripath at McLeod Health Loris successful. A4. Potential Negative Outcome If McLeod Health Loris fails to implement the Steripath device, the hospital will most probably continue experiencing the issues that arise due to t...